Cell Therapeutics Responding To Inquiry Into Trisenox Off-Label Promotions

Seattle, Wash. U.S. attorney's office is investigating marketing practices for CTI's leukemia agent. The company's recent 10-Q filing acknowledges that Trisenox is "largely" prescribed off-label and some instances of off-label promotions have "likely" occurred.